In today’s recent session, 1.0 million shares of the Editas Medicine Inc (NASDAQ:EDIT) have been traded, and its beta is 2.09. Most recently the company’s share price was $1.76, and it changed around $0.21 or 13.87% from the last close, which brings the market valuation of the company to $147.75M. EDIT at last check was trading at a discount to its 52-week high of $6.22, offering almost -253.41% off that amount. The share price’s 52-week low was $0.91, which indicates that the recent value has risen by an impressive 48.3% since then. We note from Editas Medicine Inc’s average daily trading volume that its 10-day average is 1.8 million shares, with the 3-month average coming to 2.34 million.
Editas Medicine Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.50. If we narrow it down even further, the data shows that 0 out of 16 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 9 recommended EDIT as a Hold, whereas 4 deemed it a Buy, and 2 rated it as Underweight.
Editas Medicine Inc (NASDAQ:EDIT) trade information
Instantly EDIT has been showing a green trend so far today with a performance of 13.87% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.6700 on recent trading daydecreased the stock’s daily price by -5.39%. The company’s shares are currently up 38.98% year-to-date, but still up 18.46% over the last five days. On the other hand, Editas Medicine Inc (NASDAQ:EDIT) is 14.61% up in the 30-day period. We can see from the shorts that 11.61 million shares have been sold at a short interest cover period of 5.53 day(s).
The consensus price target as assigned by Wall Street analysts is $12, which translates to bulls needing to increase their stock price by 85.33% from its current value. Analyst projections state that EDIT is forecast to be at a low of $5 and a high of $35.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -1.48%. Editas Medicine Inc earnings are expected to increase by 36.08% in 2025, but the outlook is positive 26.11% per year for the next five years.
EDIT Dividends
Editas Medicine Inc’s next quarterly earnings report is expected to be released on 2025-May-11.
Editas Medicine Inc (NASDAQ:EDIT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.35% of Editas Medicine Inc shares, and 56.42% of them are in the hands of institutional investors. The stock currently has a share float of 56.62%. Editas Medicine Inc stock is held by 253.0 institutions, with VANGUARD GROUP INC being the largest institutional investor. By 2024-06-30, it held 9.7589% of the shares, which is about 8.03 million shares worth $37.51 million.
BLACKROCK INC., with 9.4551% or 7.78 million shares worth $36.34 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 2.59 shares worth $4.56 million, making up 3.10% of all outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held roughly 2.19 shares worth around $3.86 million, which represents about 2.62% of the total shares outstanding.
